Chemomab Therapeutics CFO Sigal Fattal Form 3 Filing - Stock Ownership and Equity Awards

This Form 3 filing discloses the initial statement of beneficial ownership of securities by Sigal Fattal, Chief Financial Officer of Chemomab Therapeutics Ltd. The filing shows Fattal's ownership of 9,728 American Depositary Shares (ADS) directly, plus 15,222 ADS in restricted share units (RSUs) granted on October 1, 2024, and 12,500 ADS in RSUs granted on April 10, 2025. The RSUs vest over multi-year schedules extending through 2028 and 2029. Additionally, Fattal holds stock options for 8,900 ADS (granted November 2021, fully vested), 7,350 ADS (granted November 2022, vesting through 2026), and 25,715 ADS (granted June 2023, vesting through 2027) with exercise prices ranging from $6.80 to $39.31 per ADS. The filing was submitted under temporary relief for foreign private issuers and covers the period ending March 18, 2026.